The company’s newest cannabinoid formulation treats patients with chemotherapy-induced nausea and vomiting (CINV).
's () newest cannabinoid formulation, NanoCBD, is now available in Australia, with the first patient supplied under the Australian Government’s Special Access Scheme (SAS)
The drug is intended for the treatment of patients with chemotherapy-induced nausea and vomiting (CINV), and like NanaBis™, shares the same proprietary delivery platform, NanoCelle™.
MDC's chief executive officer Dr Sean Hall said: “NanoCBD is a fantastic product to be supplied alongside our lead drug candidate NanaBis™.
“Unlike NanaBis, NanoCBD is a CBD only product, but like NanaBis™ it is a further example of the optionality of our NanoCelle™ delivery system.”
Beyond Australia and Hong Kong, where the first shipment of NanoCBD has also recently been received, Medlab is now focusing discussions on trade expansion in the Northern Hemisphere markets.
CBD only formulation
NanoCBD is a CBD only formulation, manufactured in a US, Food and Drug Administration (FDA) approved facility, with analytical work conducted at a US FDA approved testing laboratory.
Unlike other CBD oils, tablets, or capsules the drug:
Is a submicron spray validated to be 21.29 nanometres delivering 5 milligrams/0.3 millilitres, Is not subject to known product degradation (1st pass metabolism) as it is administered to the oro-buccal membrane and not ingested, and Mechanistically utilises the facial lymphatics for systemic delivery, allowing a more rapid response.Clinical trials planned
In parallel to being made available under the SAS, NanoCBD will undergo clinical trials for the treatment of CINV for drug approvals.
Dr Hall said: “NanoCBD is manufactured to a drug standard, and because it shares a number of similarities to NanaBis™, we believe NanoCBD is well placed to offer a more scientific and medically plausible offering in global markets.”
